Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis

Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
Enrolling By Invitation
18 years - 70 years
All
Phase 3
5 participants needed
1 Location

Brief description of study

To investigate the safety and efficacy of Tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Diabetic Gastroparesis
  • Age: 18 years - 70 years
  • Gender: All

Male or Female, Age 18-70, Diagnosed with gastroparesis

Updated on 02 Jul 2025. Study ID: 19-0972
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research